The ACUITY Trial: A randomized comparison of Angiomax (bivalirudin) versus heparin (unfractionated heparin or enoxaparin ) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation
Description of Research
Bivalirudin is a new drug approved in the USA, Canada, New Zealand and Israel for use in patients that may need angioplasty. Trials suggest that bivalirudin may reduce the chance of bleeding, heart attack or need for an urgent repeat angiography procedure in patients at high risk of developing complications. The primary purpose of this study is to compare the effectiveness of type I drugs, i.e. enoxaparin, to the study drug bivalirudin, for the prevention of blood clots and bleeding.